Certain principles common to the treatment of HIV-infected patients with cancer apply to various malignant conditions. Treatment of such patients is complex and requires knowledge and understanding of both oncology and HIV infection. Problems encountered while treating patients with malignancy include:

- Immunosuppression induced by chemotherapy can further compromise the immunocellular deficit of HIV-infected patients and might facilitate the onset of OIs and/or the evolution of the HIV infection itself.
- In patients with non-AIDS-defining malignancies, the CD4+ count is usually normal or slightly decreased at diagnosis, but may become severely depressed during and after treatment, resulting in a higher susceptibility to OIs.
- HIV-associated leukopenia, due to HIV-myelodysplasia or nucleoside analogue therapy, makes the administration of conventional dosages of chemotherapy difficult.
- Tolerance to chemotherapy in HIV-infected patients is generally poor and requires frequent dose reductions and/or delays in therapy.

The goals of cancer therapy, curative versus palliative, and the status of the underlying HIV infection must be evaluated in each individual case (Table I). Treatment should include therapy for opportunistic infections (OIs) and the underlying HIV.

### HODGKIN’S DISEASE

HD is the most common non-AIDS-defining tumour. The relative risk for HD in HIV-infected patients is consistent from study to study. Although evidence suggests that HD might be associated with HIV-infected intravenous drug users, it does not appear to be restricted to this group only. The relationship between HD and HIV remains controversial and is not clearly understood. Despite these findings, it has been argued that both AIDS and HD affect patients in the 3rd and 4th decade of life, and that the association is merely coincidental. The relative risk for the development of HD in HIV-infected individuals varies from 7.9 to 8.5 in different studies.

However, when HD occurs, the presentation of disease in the HIV-infected patient differs from that in the HIV-negative individual. Investigators have noted that AIDS-HD is likely to
appear in younger patients, with a higher prevalence in males, and more advanced disease, stage III or IV (75 - 89%), at presentation. A higher percentage have B-symptoms (83%), which include night sweats, unexplained weight loss of more than 10%, pruritus and Pel Ebstein fever, and extranodal disease (63%), and patients are less likely to be cured (response rate 44 - 79%). AIDS-HD is characterised by the predominance of unfavourable subtypes, with mixed-cellularity or lymphocyte-depleted (53 - 63%) the most frequently diagnosed histological types. A high frequency (80 - 100%) of Epstein-Barr virus (EBV) has been identified in tissue from HIV-infected HD patients and might represent a factor involved in the pathogenesis of HIV-associated HD. Data from Carbone et al. display the bcl-6 syn-1 positive Reed-Sternberg phenotype HD cells, reflecting the post-germinal centre B-cell origin in the HIV-infected population. In contrast to the general population, HD Reed-Sternberg cells derive from germinal centre B-cells.

**TREATMENT**

The optimal therapy for AIDS-HD has not been defined. Considering that HD is an earlier manifestation of HIV infection than NHL (higher CD4+ cell count at presentation), the treatment approach for the two entities might be different (Fig. 1). Most patients present with advanced disease and have been treated with combination chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), but response rates remain dismal. Tolerance to chemotherapy has been poor and frequent dose reductions and/or delays in therapy are required. Response to therapy is far below that seen in the general population with HD, with a reported 1.5 years median overall survival. In the HIV-negative population more than 80% of patients with HD are alive at 10 years.

**Fig. 1.** Hodgkin’s disease (a) at presentation, and (b) after 4 cycles of chemotherapy (c) Simulator film for radiation therapy.

A study from the M D Anderson Cancer Center reported a 5-year overall survival rate of 54% with combination therapy (chemo- and radiotherapy) in AIDS-HD patients. In an attempt to improve response and survival rates, Zittoun et al. conducted a study with HAART-EBVP (epirubicin, bleomycin, vinblastine and prednisone) and *Pneumocystis carinii* pneumonia prophylaxis. Results of the trial showed an improved complete response rate of 74%. The 3-year disease-free survival and 3-year overall survival rates were 53% and 32% respectively, with the cause of death HD progression and OIs in 48% and 9% of patients. A prospective phase II study using a short-term Stanford V regimen with adjuvant radiotherapy showed this to be an active and feasible regimen in the setting of AIDS-HD, and concluded that the use of concomitant HAART does not increase chemotherapy-related toxicity. Owing to the aggressive nature and advanced stages of AIDS-HD, more effective combined systemic anti-cancer and HAART therapy is required and should be used to improve the response and disease-free survival of AIDS-HD patients.

**ANAL CARCINOMA**

Several reports have suggested a slight increase in the incidence of squamous cell cancer of the anus associated with the HIV epidemic. It is important to note that anal cancer was on the rise among homosexual men before the AIDS epidemic, owing to anogenital warts and sexual transmission of the human papillomavirus (HPV). A high incidence of the human papilloma 16-type virus is associated with high-grade intraepithelial neoplasia (AIN) and invasive cancer. It appears that HIV-induced immunosuppression allows reactivation of HPV, which leads to epithelial abnormalities. The incidence of AIN is significantly higher in homosexual men with HPV (61%) than in heterosexual men with HPV (4%). The incidence of anal cancer in HIV-positive men has been estimated at 70 per 100 000 persons per year. However, it is unclear whether the increase in anal cancer is directly linked to HIV alone.

**TREATMENT**

Anal cancer is very sensitive to combined-modality treatment (CMT) with chemoradiation therapy and is a highly curable cancer with a 65 - 75% long-term survival rate in the general population. Data suggest that HIV-infected patients with anal cancer should be managed with the same treatment as HIV-negative individuals.

Two phase III randomised trials by the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) showed the benefit of adding chemotherapy to radiation and led to the general acceptance of 5-fluorouracil/mitomycin C and radiation therapy as the standard of care. Radiation fields are designed to cover the main lesion, inguinal nodes, and low pelvic nodes. In patients with advanced HIV (CD4+ counts < 200/μl) mitomycin C should be withheld owing to the potential for severe myelosuppression and haemolytic-uraemic syndrome. There is evidence that HIV-infected patients who require therapy breaks (> 10 days) from chemoradiation due to severe skin reactions (Fig. 2) and dose reductions due to chemotherapy-related neutropenia have a higher incidence of local recurrence and a shorter survival. In several small trials 40 - 80% of patients remain disease free, with a median follow-up ranging from 8 to 38 months. Prophylaxis against OIs and HAART is highly recommended during this period of potential iatrogenic immunosuppression.

For patients with advanced disease whose life expectancy is measured in months, a palliative approach is appropriate. The main goal is to relieve pain and bleeding, allowing patients to maintain their dignity and quality of life. A short course of radiation is well tolerated and recommended. Great care should be taken not to irradiate bowel unnecessarily in a
population that might already be suffering from diseases such as chronic diarrhoea due to Cryptosporidium infections. As patients continue to live longer because of improved antiretroviral and prophylactic therapy, a rise in the incidence of invasive anal cancer is expected, which argues for better surveillance and screening for anal squamous intraepithelial lesions by anoscopy, cytology, and polymerase chain reaction (PCR) for HPV.

OTHER MALIGNANCIES IN THE HIV SETTING

HIV infection promotes immunosuppression which in turn fosters the development of malignancies. For most cancers, the higher prevalence is probably attributed to lifestyle factors among people with HIV. Malignancies may occur for reasons unrelated to immunosuppression, such as smoking and exposure to sexually transmitted HPV. As the AIDS epidemic advances, other tumours are increasingly seen in HIV-infected patients, including testicular cancer, lung cancer and basal cell carcinoma of the skin.

TESTICULAR CANCER

Recent data indicate that HIV-positive men have a significantly higher incidence of testicular cancer than the general population. An Italian series of HIV patients with testicular germ cell tumours (GCT) suggested that the association between testicular cancer and HIV is not directly related to immune function. The increase in seminoma was seen predominantly in homosexual males and white men. The majority of HIV-infected patients with GCT tolerate standard chemotherapy well and the majority obtain cure rates similar to those in the general population (Fig. 3). Treatment should include therapy for the underlying HIV and opportunistic infections (OIs).

LUNG CANCER

Epidemiological data do not support an increased incidence of lung cancer in the HIV-infected population. Tobacco smoking seems to be the major carcinogenic agent in both the HIV-infected and the general population. However, different features of lung cancer are observed in HIV-infected patients. The median age at presentation is younger, with adenocarcinoma being the predominant histological subtype. More than 70% of HIV patients present with advanced stages of disease, including 55% with metastatic disease at the time of diagnosis. Survival of HIV-positive patients with lung cancer remains poor, with a median survival of 6 months and only 10% of patients alive 1 year after diagnosis. If the HIV is under control, lung cancer should be managed with the same therapeutic strategies as in the general population.

CONCLUSION

Epidemiological reviews have failed to show a significant rise in the incidence of other malignancies in the HIV/AIDS setting. With the improvement in antiretroviral therapy and appropriate prophylaxis for OIs, life expectancy for patients with AIDS will continue to improve. Consideration should be given to the use of HAART and appropriate prophylaxis for OIs during treatment with radiation and/or chemotherapy for any of these diseases.

Data regarding the influence of HAART on the prognosis of malignancies remain difficult to interpret, with some studies claiming improved survival, e.g. for patients with NHL, whereas others claim no influence. Therapeutic decisions should be based on the HIV patient's current location on the timeline of his or her disease. Patients with CD4+ counts above 200 cells/μl tolerate anti-neoplastic therapy as well as the general population but may suffer from long-term bone marrow and bowel toxicities. While HAART has improved morbidity and mortality in HIV-infected patients, malignant neoplasms and their successful treatment remain a challenge.
REFERENCES


